NCOA2 and chondrosarcoma: Mesenchymal chondrosarcoma (MCS) is characterised by small round cell biology with frequent HEY1-NCOA2 fusion, early haematogenous spread, and greater sensitivity to systemic chemotherapy (CHT) than other chondrosarcoma subtypes.